AEGiS-PRn: Antibacterial, Antifungal, & Antiviral Drug Discovery Conferences To Take Place March 11-14, 2002 in Princeton, NJ

Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.

Antibacterial, Antifungal, & Antiviral Drug Discovery Conferences To Take Place March 11-14, 2002 in Princeton, NJ

PRNewswire - December 3, 2001

PRINCETON, N.J., Dec. 3 /PRNewswire/ -- The World Antibacterial, Antifungal, & Antiviral research communities will convene in Princeton, NJ this coming March to attend the "7th Antibacterial Drug Discovery & Development Summit" on March 11-12, and the "6th Antifungal Drug Discovery & Development Summit" and "3rd International Antiviral Drug Discovery & Development Summit," the latter two to take place concurrently on March 13-14, announces Strategic Research Institute.

The related meetings are offered in conjunction as part of the "Tri-Anti-Microbial World Summit", annually held in March.

The 2002 Antibacterial meeting features clinical compounds, novel targets, pre-clinical lead compounds, antimicrobial peptides, proteomic and microarray applications, novel screens and assays, quorem sensing, structure-based approaches, aerosolized antibiotics, and bioterrorism -- industry implications, among many other topics.

The 2002 Antifungal meeting features clinical updates on Cancidas, Posaconazole, and Micafungin, as well as new targets, compound classes, proteomic and other genomic strategies, agricultural funcicide discovery, and lipid-based delivery systems, plus other topics. The meeting is co-keynoted by David Warnock, MD, Center for Disease Control & Prevention, and Andreas Groll, MD, National Cancer Institute. Their keynote talks are titled "Epidemiologic Aspects, Management and Prevention of Fungal Infections," and "Antifungal Therapeutics in the Clinic," respectively.

The 2002 Antiviral & Vaccine meeting is organized around discovery and development efforts in HIV, HBV/HCV, HPV, RSV, influenza, and vaccine research & development. The addition of the vaccine section in 2002 expands the scope of the agenda beyond antiviral efforts that characterized the first two meetings.

To request the agenda(s) and/or to inquire about conference sponsorship/exhibition, please contact Jacqueline Ni at jni@srinstitute.com; please specify the meeting(s) of interest, and include full contact information (with fax number).

SOURCE Strategic Research Institute Web Site: http://www.srinstitute.com

011203
PR011204

Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .